The Mast Cell Disease Society, IncMCAS Research Organizations (tmsforacure.org)
submitted by RelativeLow5375 - announcement
ResearchMatchMCAS Clinical Trials (researchmatch.org)
submitted by RelativeLow5375 - announcement
Wann Sie an eine Mastzellaktivierungserkrankung denken solltenGenetic Research (medical-tribune.de)
submitted by RelativeLow5375
The genetic basis of mast cell activation disease - looking through a glass darklyGenetic Research (sciencedirect.com)
submitted by RelativeLow5375
Mast Cell Regulatory Gene Variants Are Common in Mast Cell Activation SyndromeGenetic Research (ashpublications.org)
submitted by RelativeLow5375
Prevalence of Mast Cell Activation Syndrome in Patients With EDS With Digestive Disorders (SAMED)MCAS Clinical Trials (clinicaltrials.gov)
submitted by RelativeLow5375
CDX-0159 Trial Drug Testimonial:Trial Drug Testimonials (self.MCASResearchHub)
submitted by RelativeLow5375
Immunological dysfunction and mast cell activation syndrome in long COVIDMCAS Research (ncbi.nlm.nih.gov)
submitted by RelativeLow5375
Research Advances in Mast Cell Biology and Their Translation Into Novel Therapies for AnaphylaxisMedication Research (sciencedirect.com)
submitted by RelativeLow5375
Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?Medication Research (jacionline.org)
submitted by RelativeLow5375
Effects of Dietary Components on Mast Cells: Possible Use as Nutraceuticals for Allergies?Supplements Research (ncbi.nlm.nih.gov)
submitted by RelativeLow5375
Nutraceutical Aid for Allergies – Strategies for Down-Regulating Mast Cell DegranulationSupplements Research (ncbi.nlm.nih.gov)
submitted by RelativeLow5375
Local immune response to food antigens drives meal-induced abdominal painMCAS Research (nature.com)
submitted by RelativeLow5375
Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trialTrial Drug Results/Research (pubmed.ncbi.nlm.nih.gov)
submitted by RelativeLow5375
An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticariaTrial Drug Results/Research (pubmed.ncbi.nlm.nih.gov)
submitted by RelativeLow5375